Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY Begins GOBLET Anal Cancer Cohort Enrollment Expansion

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Mar 16, 2024 6:00pm

94 Views

Post# 35936819

RE:ONCY Begins GOBLET Anal Cancer Cohort Enrollment Expansion

Hello Note and maybe you can help clarify something for me as it was my understanding that as a result of the recent pr in regards to the anal study that onc had actually started enrollment in expansion phase of this trial. Is that how you would read this news release

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season